NanotheaS.A.
Research and experimental development in natural sciences and engineering
Overview
Nanothea is a company that develops innovative radiopharmaceuticals for the diagnosis and treatment of cancer. They focus on creating precise methods using radioisotopes combined with nanoparticles and targeting conjugates to improve the effectiveness of radiotherapy while minimizing side effects. Their products are designed to ensure non-toxic, FDA-approved materials for safe therapeutic delivery directly to tumors.
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-01-11. Active
16 1090 1056 0000 0001 3132 3692- 59 1090 1870 0000 0001 3704 2883
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 5, 2017 | Commercial Companies Code notice | |
| Apr 19, 2016 | Commercial Companies Code notice |
Public aid
6 public aid cases recorded, with a total value of $1,695,336.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 17, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy | |
| Apr 24, 2017 | Aid for research and development projects: industrial research | $299.3K$299,290 | MARSZAŁEK MAZOWIECKI | |
| Apr 24, 2017 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $6,814$6,814 | MARSZAŁEK MAZOWIECKI |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-10-01 | Biopolimerowe nanocząstki jako nośniki izotopów promieniotwórczych do wczesnej diagnostyki nowotworów | $1.3M$1,329,441 | Program Operacyjny Inteligentny Rozwój | |
| 2016-06-07 | Opracowanie biopolimerowych nanocząstek do precyzyjnej diagnostyki oraz celowanej terapii nowotworu prostaty z wykorzystaniem radioizotopów | $293.6K$293,553 | Regionalny Program Operacyjny Województwa Mazowieckiego na lata 2014-2020 |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Tomasz Adam Ciach (61)  | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Przemysław Daniel Mazurek (50) | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Piotr Paweł Mierzejewski (62) | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| L-Conesp. z o.o. | $803.90 | l-cone.pl | ||
| Nanoemisp. z o.o. | $62.52 | nanoemi.pl | ||
| Ncage TherapeuticsS.A. | $29.14 | ncage.org |
Change history
| Date | Event | |
|---|---|---|
| 2025-09-23 | PKD change (Removed: 70.22.Z, 71.12.Z, 71.20.B, 72.11.Z, 72.19.Z, 74.90.Z; Added: 70.20.Z, 71.12.B, 71.20.C, 72.10.Z, 74.91) | |
| 2024-12-24 | Share capital change (282,944.00 PLN → 298,645.00 PLN) | |
| 2023-09-07 | Share capital change (252,944.00 PLN → 282,944.00 PLN) | |
| 2023-06-12 | Share capital change (157,063.00 PLN → 252,944.00 PLN) | |
| 2022-05-26 | Share capital change (153,123.00 PLN → 157,063.00 PLN) |
FAQ
Last updated: 2026-07-17